PARATHYROID DISORDERS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Parathyroid Disorders Market Size and Forecast – 2025 to 2032

The Global Parathyroid Disorders Market is estimated to be valued at USD 11.10 Bn in 2025 and is expected to reach USD 13.93 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2025 to 2032. The market growth is driven by factors such as the increasing prevalence of parathyroid disorders, rising awareness about the importance of early diagnosis and treatment, and advancements in diagnostic technologies and surgical techniques.

Key Takeaways of the Global Parathyroid Disorders Market:

• In 2025, the drug class segment is expected to hold the largest share of the market at 52.6%.
• Among disorder types, primary hyperparathyroidism is expected to account for the highest market share at 42.1% in 2025.
• The oral segment is expected to lead the market with a 53.1% share in 2025.
• North America is expected to lead the market, holding a share of 38.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 34.2% in 2025.

Market Overview:

The market trend for the global parathyroid disorders market is characterized by a growing emphasis on minimally invasive surgical procedures, such as parathyroidectomy, which offer faster recovery times and reduced complications compared to traditional open surgeries. Additionally, there is a rising demand for targeted drug therapies and personalized treatment approaches, as well as an increasing focus on research and development activities to identify novel biomarkers and develop innovative diagnostic and therapeutic solutions for parathyroid disorders.

Currents Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Analysis

To learn more about this report, Request sample copy

Parathyroid Disorders Market Insights, By Type - Advancements in Drug Class Drive the Parathyroid Disorders Market

In terms of type, drug class is expected to contribute the highest share of the market with 52.6% in 2025 owing to the continuous advancements and innovations in the pharmaceutical industry. The drug class segment encompasses various categories, including Parathyroid Hormone (PTH) analogues, bisphosphonates, calcimimetics, vitamin d analogues, and phosphate binders, each targeting specific aspects of parathyroid disorders.

PTH analogues have gained significant attention due to their ability to mimic the effects of natural parathyroid hormone, thereby regulating calcium levels in the body. These drugs have proven to be highly effective in treating hypoparathyroidism, a condition characterized by insufficient parathyroid hormone production. The increasing prevalence of hypoparathyroidism and the growing awareness about the benefits of PTH analogues have fueled their demand in the market.

Parathyroid Disorders Market Insights, By Disorder Type - Growing Elderly Population Drives Demand for Targeted Diagnostics and Therapies

In terms of disorder type, primary hyperparathyroidism is expected to contribute the highest share of the parathyroid disorders market with a share of 42.1% in 2025. Primary hyperparathyroidism is a condition characterized by the overproduction of parathyroid hormone (PTH) due to the development of a benign tumor or hyperplasia of one or more parathyroid glands. This excess PTH leads to elevated calcium levels in the blood, which can cause a wide range of symptoms and complications.

The increasing prevalence of primary hyperparathyroidism worldwide is a significant factor driving its dominant market share. Studies have shown that the incidence of primary hyperparathyroidism increases with age, and with the growing aging population, the demand for effective diagnostic and therapeutic options for this disorder has risen substantially.

Parathyroid Disorders Market Insights, By Rute of Administration - Oral Administration Dominates Due to Convenience and High Compliance

The oral segment is expected to dominate the parathyroid disorders market with a share of 53.1% in 2025 due to its convenience, affordability, and widespread use in managing conditions like hypoparathyroidism. Patients prefer oral medications such as calcium and vitamin D supplements because they are easy to take, require no clinical assistance, and support long-term adherence. This non-invasive route significantly enhances patient compliance, making it the most commonly adopted method for routine treatment.

While parenteral administration—such as injections of recombinant parathyroid hormone therapies like Natpara and Yorvipath—is gaining traction for patients with more severe or unresponsive conditions, the convenience and affordability of oral medications continue to make them the preferred choice for most patients.

Reimbursement Scenario for the Global Parathyroid Disorders Market

• The reimbursement scenario for the global parathyroid disorders market varies widely across regions. In developed countries, treatments for conditions like hyperparathyroidism often receive coverage through national health systems or private insurance, influenced by the U.S. FDA approvals and clinical efficacy data. In contrast, emerging markets may offer limited reimbursement options, leading to high out-of-pocket costs for patients and complicating access to necessary therapies.
• Parathyroid Hormone (PTH), Calcium, Phosphorus, and Magnesium tests are typically reimbursed under specific clinical conditions. Coverage is granted when these tests are deemed medically necessary, such as in cases of abnormal calcium levels, parathyroid-related disorders (e.g., hyperparathyroidism, hypoparathyroidism, pseudohypoparathyroidism), chronic kidney disease, osteoporosis, or genetic conditions like MEN2A.
• Routine screening or wellness-based testing without symptoms or abnormal findings is generally not reimbursed, as it lacks scientific justification. Additionally, advanced PTH metabolite testing (e.g., amino-terminal or carboxy-terminal fragments) is also not covered due to insufficient clinical evidence. Reimbursement is guided by clear clinical indications, test frequency limitations, and individual health plan policies, reflecting a broader global trend toward value-based diagnostics and evidence-driven healthcare reimbursement in the parathyroid disorders space.

Regional Insights

To learn more about this report, Request sample copy

North America Parathyroid Disorders Market Analysis and Trends

North America’s dominance in the global parathyroid disorders market with an estimated share of 38.3% in 2025 can be attributed to several factors. The region boasts a well-established healthcare infrastructure, coupled with high awareness about parathyroid disorders among both patients and healthcare professionals. The presence of leading pharmaceutical and biotechnology companies, such as Amgen, Eli Lilly, and Abbott Laboratories, further strengthens the market ecosystem. These companies actively invest in research and development, driving innovation in diagnostic tools and treatment options for parathyroid disorders.

Moreover, favorable reimbursement policies and government initiatives aimed at improving patient care contribute to the region's dominance. The U.S., in particular, plays a significant role in shaping the market landscape, with its advanced medical facilities, skilled healthcare workforce, and supportive regulatory environment.

Asia Pacific Parathyroid Disorders Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth in the global parathyroid disorders market with a share of 34.2% in 2025. This growth can be ascribed to the rapidly expanding healthcare sector, increasing disposable incomes, and rising awareness about parathyroid disorders in the region. Countries such as China, India, and Japan are witnessing significant improvements in their healthcare infrastructure, making advanced diagnostic and treatment options more accessible to patients.

Furthermore, the growing prevalence of conditions such as hypercalcemia and hyperparathyroidism, often associated with parathyroid disorders, is driving the demand for effective management solutions. Local companies, such as Kyowa Kirin and Taisho Pharmaceutical, are actively collaborating with international players to introduce innovative products and expand their market presence. Government initiatives promoting healthcare reforms and increasing investments in research and development further contribute to the region's fast-paced growth.

Global Parathyroid Disorders Market Outlook for Key Countries:

U.S. Parathyroid Disorders Market Trends

The U.S. market for parathyroid disorders is characterized by a strong focus on research and development, with major players like Amgen and Eli Lilly at the forefront. These companies are investing in the development of novel therapies and diagnostic tools, aiming to improve patient outcomes. The country's advanced healthcare infrastructure, coupled with a high prevalence of parathyroid disorders, drives the demand for effective treatment options.

For instance, in March 2024, AstraZeneca, a global drugmaker, bought Amolyt Pharma for USD 800 million to expand into rare endocrine diseases. The deal gave AstraZeneca eneboparatide, a Phase 3 drug for hypoparathyroidism, which may help patients maintain normal calcium levels without needing daily supplements.

China Parathyroid Disorders Market Trends

China's market for parathyroid disorders is experiencing rapid growth, driven by increasing healthcare expenditure, a large patient population, and rising awareness about these conditions. The government's initiatives to improve healthcare access and quality are facilitating the adoption of advanced diagnostic and treatment options. Local companies are collaborating with international players to introduce innovative products and expand their market reach.

For instance, in February 2022, researchers from the Shenzhen Institute of Advanced Technology (SIAT), part of the Chinese Academy of Sciences, developed an innovative optogenetic method to regulate parathyroid hormone (PTH) secretion, aiming to prevent bone loss linked to secondary hyperparathyroidism (SHPT).

Germany Parathyroid Disorders Market Trends

Germany continues to lead the European market for parathyroid disorders, backed by its strong healthcare system, advanced medical research, and a focus on precision medicine. The country's leading pharmaceutical companies, such as Merck KGaA and Bayer AG, are actively involved in developing and commercializing innovative therapies for parathyroid disorders. Germany's well-established reimbursement policies and a high standard of patient care contribute to the market's steady growth. In January 2022, according to Oxford University Press, the 2021 PARAT Working Group, under the European Society of Endocrinology (ESE), published expert recommendations in the European Journal of Endocrinology for the practical management of primary hyperparathyroidism (PHPT), chronic hypoparathyroidism (HypoPT), and parathyroid disorders during pregnancy and lactation.

Japan Parathyroid Disorders Market Trends

Japan's market for parathyroid disorders is characterized by a sophisticated healthcare system, advanced medical technology, and a rapidly aging population. The country's leading pharmaceutical companies, such as Kyowa Kirin and Taisho Pharmaceutical, are at the forefront of developing and commercializing novel therapies for parathyroid disorders. Japan's government is actively promoting research and development in the healthcare sector, fostering innovation and collaboration among industry players. The increasing prevalence of calcium-related disorders and the growing awareness about the importance of early diagnosis and treatment are driving the market's growth.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Request sample copy

Key Developments:

• In September 2024, Septerna, a clinical-stage biotech company focused on GPCR-targeted drug discovery, presented promising preclinical data at ASBMR 2024 for its oral PTH1R agonists targeting hypoparathyroidism. Its lead candidate, SEP-786, showed improved serum calcium control, enhanced bone turnover biomarkers, and increased active vitamin D levels over 28 days in preclinical models.
• In August 2024, the U.S. FDA has approved Yorvipath (palopegteriparatide), a subcutaneous injection for treating adults with hypoparathyroidism. The approval excludes use in patients with acute post-surgical hypoparathyroidism, as they were not part of the study.
• In January 2024, Ascendis Pharma, a Denmark-based biopharmaceutical company specializing in rare endocrine disorders, launched YORVIPATH (palopegteriparatide) in Germany and Austria. Developed using its proprietary TransCon technology, YORVIPATH is a parathyroid hormone replacement therapy for adults with chronic hypoparathyroidism. This marks the company's second commercial product built on the TransCon platform.

Top Strategies Followed by Global Parathyroid Disorders Market Players

• Established players in the global parathyroid disorders market prioritize extensive research and development to innovate high-performance products. These companies invest heavily in R&D to develop cutting-edge treatments and diagnostic tools for parathyroid disorders. Additionally, strategic partnerships with major industry players and original equipment manufacturers (OEMs) are crucial for solidifying market presence.
  • In March 2025, Alexion, AstraZeneca’s Rare Disease unit, announced that its investigational drug eneboparatide (AZP-3601) met the primary endpoint in the CALYPSO Phase III trial for treating chronic hypoparathyroidism. The trial showed statistically significant normalization of serum calcium levels and reduced dependency on active vitamin D and calcium therapy at 24 weeks.

• Mid-level players, such as Radius Health, are developing cost-effective PTH analogs while offering patient-friendly delivery systems like transdermal patches. Their focus on affordable innovation attracts a broader consumer base, especially in emerging economies. These companies also engage in collaborations to advance their R&D capabilities.
  • For instance, in July 2020, Entera Bio, a biotech company, partnered with academic institutions to develop oral formulations for parathyroid-related conditions, aiming for improved patient compliance and broader reach.

• Small-scale players in the global parathyroid disorders market often specialize in niche areas, offering unique features or innovative products. By targeting specific market segments, these players can differentiate themselves and capture a loyal customer base. Additionally, small-scale players actively adopt cutting-edge technologies to remain competitive in the market.
  • In June 2021, OPKO Health Inc., a biopharmaceutical company through its subsidiary EirGen Pharma, signed an agreement with Nicoya Macau Limited—an affiliate of Nicoya Therapeutics—for the development and commercialization of RAYALDEE in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). RAYALDEE is intended for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD).

Market Report Scope

Parathyroid Disorders Market Dynamics

To learn more about this report, Request sample copy

Parathyroid Disorders Market Driver - Increasing prevalence of chronic kidney disease leading to secondary hyperparathyroidism

The rising prevalence of chronic kidney disease (CKD) worldwide is a significant driver for the growth of the global parathyroid disorders market. As CKD progresses, it often leads to the development of secondary hyperparathyroidism, a condition characterized by the overproduction of parathyroid hormone (PTH) in response to decreased kidney function and impaired mineral metabolism. The accumulation of PTH in the body can cause a range of complications, including bone disorders, cardiovascular problems, and other systemic issues. With the increasing global burden of CKD, the incidence of secondary hyperparathyroidism is expected to rise, driving the demand for effective treatments and management strategies for parathyroid disorders. This growing patient population is likely to fuel the expansion of the parathyroid disorders market, as healthcare providers seek innovative solutions to address the complex needs of individuals with secondary hyperparathyroidism and related conditions.

For instance, according to research by International Journal of Advances in Medicine, a recent cross-sectional study involving 100 chronic kidney disease (CKD) patients revealed that 22% suffer from secondary hyperparathyroidism (SHPT), a frequently overlooked complication. The study found SHPT prevalence significantly higher in dialysis patients (30%) compared to non-dialysis patients (14%). Researchers emphasized the importance of early monitoring of parathyroid hormone (PTH) levels, as SHPT typically develops when eGFR drops below 60 ml/min.

Parathyroid Disorders Market Opportunity - Development of novel recombinant parathyroid hormone therapies

The development of novel recombinant parathyroid hormone therapies presents a significant opportunity for the Global Parathyroid Disorders Market. Recombinant parathyroid hormone (rhPTH) therapies have emerged as a promising alternative to traditional treatments, offering a more targeted and efficient approach to managing parathyroid disorders. These therapies involve the use of genetically engineered parathyroid hormone, which can help regulate calcium levels in the body and alleviate the symptoms associated with parathyroid disorders. The potential benefits of rhPTH therapies include reduced treatment duration, improved patient outcomes, and fewer side effects compared to conventional surgical interventions. Additionally, the development of long-acting rhPTH formulations could further enhance patient convenience and adherence to treatment.

According to Oxford University Press, in June 2024, a new investigational drug, EXT608, has demonstrated strong preclinical results for treating hypoparathyroidism, according to a study published in JBMR Plus (June 2024). Developed using D-VITylation technology, EXT608 is a parathyroid hormone (PTH) derivative with an extended half-life, offering sustained calcium regulation.

Analyst Opinion (Expert Opinion) 

• The global parathyroid disorders market is witnessing steady growth driven by advancements in diagnostic tools, expanding therapeutic options like PTH analogues, and rising awareness of endocrine health. Regulatory support from agencies such as the U.S. FDA and EMA has fast-tracked approvals for innovative treatments, while increasing incidences of hypoparathyroidism and hyperparathyroidism globally continue to create demand for effective management solutions. However, the market faces challenges such as limited awareness in emerging economies, high treatment costs, and a small patient pool for certain rare parathyroid conditions. Still, opportunities are emerging in AI-powered diagnostics, minimally invasive parathyroid surgeries, and the integration of digital health tools for remote patient monitoring.
• Notable initiatives include AstraZeneca’s acquisition of Amolyt Pharma in 2024, aiming to advance eneboparatide—a promising therapy for hypoparathyroidism in phase 3 trials. Events like the Endocrine Society’s Annual Meeting (ENDO 2023) and the European Congress of Endocrinology (ECE 2022, 2023) have served as important platforms for showcasing breakthroughs, regulatory updates, and collaborative research. These conferences have accelerated the adoption of novel therapies and helped shape regional health policies. With rising investments in rare endocrine disorder research and targeted drug development, the parathyroid disorders market is poised for robust innovation-led growth.

Market Segmentation

•  Type Insights (Revenue, USD Bn, 2020 - 2032)
• • Drug Class
    • Parathyroid Hormone (PTH) Analogues
    • Bisphosphonates
    • Calcimimetics
    • Vitamin D Analogues
    • Phosphate Binders
  • Diagnostic Method
    • Blood Tests
    • Imaging Techniques
    • Urine Tests
•  Disorder Type Insights (Revenue, USD Bn, 2020 - 2032)
• • Primary Hyperparathyroidism
  • Secondary Hyperparathyroidism
  • Tertiary Hyperparathyroidism
  • Hypoparathyroidism
•  Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
• • Oral
  • Parenteral
•  Age Group Insights (Revenue, USD Bn, 2020 - 2032)
• • Pediatric
  • Adult
  • Geriatric
•  Gender Insights (Revenue, USD Bn, 2020 - 2032)
• • Male
  • Female
•  End User Insights (Revenue, USD Bn, 2020 - 2032)
• • Hospitals
  • Specialty Clinics
  • Outpatient Centers
  • Research Institutes
  • Diagnostic Centers
  • Home Healthcare
•  Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sandoz (a Novartis division)
  • Otsuka Pharmaceutical Co., Ltd.

Sources

Primary Research Interviews:

• Endocrinologists specializing in calcium and bone metabolism
• Nephrologists treating CKD-related SHPT
• Obstetricians managing endocrine disorders during pregnancy
• Regulatory Affairs Managers at hospital or public health institutions
• Clinical trial investigators (PTH analogues, calcimimetics, etc.)
• Hospital procurement heads for endocrine-related therapies/devices

Databases:

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)

Magazines:

• The Pharma Letter
• Pharmaceutical Technology
• BioSpectrum Asia
• Medical Device and Diagnostic Industry (MD+DI)
• MedTech Insight
• Drug Discovery & Development

Journals:

• The Lancet Diabetes & Endocrinology
• Journal of Clinical Endocrinology & Metabolism (JCEM)
• European Journal of Endocrinology
• Nature Reviews Endocrinology
• Nephrology Dialysis Transplantation (NDT)
• Kidney International
• Endocrine Reviews
• JBMR Plus (Journal of Bone and Mineral Research)

Newspapers:

• The New York Times – Health Section
• The Guardian – Science and Health
• Reuters Health
• The Washington Post – Medical News
• BBC Health

Associations:

• European Society of Endocrinology (ESE)
• Endocrine Society (U.S.)
• American Society of Nephrology (ASN)
• International Society of Nephrology (ISN)
• International Osteoporosis Foundation (IOF)
• National Kidney Foundation (NKF)
• Hormone Health Network

Public Domain Sources:

• Directory of Open Access Journals (DOAJ) – Peer-reviewed open access content
• OpenGrey – European grey literature repository
• Healthdata.org (IHME) – Global disease burden and treatment trends

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years